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Introduction
Fas/APO-1 is a member of the TNF receptor/nerve growth factor receptor superfamily which signals apoptosis in susceptible target cells when bound by Fas/APO-1 ligand or agonistic antibodies (Thousand Oaks, CA). Anti-human BCL-2 ab was obtained from Dakopatts (Glostrup, Denmark).
Cell culture and detection of apoptosis. The glioma cell lines were maintained in DME containing 10% FCS, 1 mM glutamine and 10 ig/ ml gentamycin (6) . M07e cells were cultured in RPMI 1640 containing 5% FCS, 1 mM glutamine, 100 U/ml penicillin, 100 ,ig/ml streptomycin, 100 ,M 2-ME, and 10 ng/ml human recombinant IL-3 (28) . L-M murine fibroblasts were cultured as previously described (29) . Irradiation was performed using a 'cobalt source. Viability and proliferation were assessed by crystal violet staining and by [3H] thymidine incorporation. The methods for the detection of apoptosis including DNA agarose gel electrophoresis, quantitative fluorometric DNA fragmentation assay and in situ DNA end labeling have previously been reported (6, 27) .
Flow cytometry. For flow cytometric cell cycle analysis, M07e cells were fixed for 10 min on ice in 70% ethanol in PBS, stained with propidium iodide (50 Itg/ml) in PBS containing 100 pg/ml RNase A (30 min, 37°C), and washed twice in PBS containing 1% formaldehyde. 2634 Weller et al.
:.. j.. Figure 2 . Detection of BCL-2 protein in human malignant gliomas. Soluble protein was harvested from the glioma cells and processed for human BCL-2 Western blot as previously described (6): lane 1, MCF-7 mammary carcinoma cells as a positive control; lanes 2-6, human malignant gliomas analysed after enzymatic and mechanical dissociation; lanes 7 and 8, human malignant gliomas after 24 h passage in vitro.
min. Sections were then stained with monoclonal ab to human BCL-2 (1:50) and a biotin/avidin-peroxidase-based detection system.
To confirm BCL-2 expression in human malignant gliomas ex vivo by Western blot (6), surgically obtained tumor pieces were dissociated mechanically, digested for 1 h in collagenase/dispase (1 mg/ml), filtered through a nylon sieve (70 gm), and centrifuged. Erythrocytes were lysed by hypotonic shock treatment and the remaining cells washed in HBSS. Soluble protein was harvested as previously described (6), either immediately after this procedure, or, to eliminate a possible contamination with B or T cells, after a 24-h passage in vitro and removal of nonadherent cells.
Results
Human malignant glioma cells express BCL-2 protein in vivo. Our previous work had suggested a role for bcl-2 in the resistance of Fas/APO-1-positive human glioma cell lines to Fas/ APO-1 ab (6). Therefore we examined the expression of BCL-2 protein in human malignant gliomas in vivo by immunocytochemistry (Fig. 1 (Table I) . BCL-2 expression was mainly localized to the nuclear envelope and cytoplasm of glioma cells but also detected in tumor-infiltrating lymphocytes. Proliferating endothelial cells associated with high grade gliomas were negative (Fig. 1) . Of 7 grade IV malignant gliomas examined by Western blot (Fig. 2) totic effects of murine bcl-2 in human cells the human IL-3-dependent M07e myeloid leukemia cell line which undergoes apoptosis after withdrawal of IL-3. The expression levels of transfected murine bcl-2 and endogenous human bcl-2 in transfected bcl-2 clones were assessed by RNase protection assay and Western blot. Murine bcl-2 mRNA and BCL-2 protein were detected in the transfected bcl-2 clones but not in neo vector control cells (Fig. 3 A) . Transfection of murine bc1-2 into M07e or glioma cells did not repress endogenous BCL-2 protein (Fig. 3 B) , consistant with preserved endogenous bel-2 mRNA expression in IL-3-dependent murine cells transfected with a retrovirus encoding bcl-2 (10). Flow cytometry showed that forced expression of murine bc1-2 in the human malignant glioma cell lines LN-18, T98G and LN-229 did not alter their cell surface Fas/APO-1 expression (data not shown).
Bcl-2 inhibits IL-3 deprivation-induced apoptosis ofhuman M07e myeloid leukemia cells. We first established that a murine bcl-2 gene transfer confers protection from apoptosis in human IL-3-dependent M07e cells deprived of IL-3, confirming similar effects of murine bcl-2 in murine cells (10) . Two M07e bcl-2 clones, bcl-2-A and bcl-2-C, which expressed high levels of murine BCL-2 protein by Western blot, and M07 vector control cells (neo) showed identical growth patterns in the presence of IL-3 and arrested in GO/GI when deprived of IL-3 for 24 h. M07e clones expressing murine bc1-2 showed significantly longer survival after IL-3 deprivation than neo or parent M07e cells (Fig. 4) . The extended survival of parent or neo M07e cells corresponded to a strong expression of endogenous BCL-2 protein (Fig. 3 B) . As Bcl-2 abrogates Fas/APO-1 ab-induced apoptosis of human malignant glioma cells. In contrast to M07e myeloid leukemia cells, bcl-2 clones derived from all three glioma cell lines acquired resistance to Fas/APO-l-dependent apoptosis (Fig. 5) . A comparison of different individual clones derived from each single cell line showed that the degree of protection from Fas/APO-1 ab-induced apoptosis depended on the degree of bcl-2 transgene expression (data not shown). Single clones with a high expression level of the transgene were selected for further study (LN-18-A4, T98G-A2, LN-229-B2). Protection from Fas/APO-ldependent apoptosis was evident in the presence and absence of actinomycin D (ActD) and CHX. While the antiapoptotic effects of murine bcl-2 were most prominent in cell cultures exposed to Fas/APO-1 ab alone or to Fas/APO-l ab plus ActD, some heterogeneity was noted in glioma cell cultures cotreated with Fas/APO-1 ab and CHX. The CHX-induced augmentation of Fas/APO-1 -dependent apoptosis was significantly attenuated in LN-18 cells transfected with murine bcl-2 but only moderately in LN-229 cells and insignificantly in T98G cells (Fig. 5, left) . Data are expressed as mean percent of survival relative to survival of untreated cells or cells exposed to ActD or CHX alone (n = 3). SEM were below 5%. the experiments (data not shown). Consistent with this observation, glioma cells expressing murine bcl-2 had no growth or survival advantage over neo cells when exposed to ActD or CHX for less than 16 h. The cytotoxicity data obtained by crystal violet staining were confirmed by phase contrast microscopy. Compared with neo cells, the bcl-2 clones revealed less dissolution of the monolayer and fewer morphological alterations suggestive of apoptosis, including membrane blebbing and nuclear fragmentation (data not shown).
To determine the effects of ActD and CHX on the expression of the murine bcl-2 transgene, RNase protection and Western blot assays were performed on transfected cells that had been treated with inhibitors of RNA and protein synthesis for 16 h (Fig. 6) , corresponding to the time frame of the cytotoxicity experiments (Fig. 5) . Although murine bcl-2 mRNA levels decined within a few hours after ActD exposure, neither ActD nor CHX induced a prominent loss of transfected murine BCL-2 protein within 16 h (Fig. 6) . Thus, the augmentation of Fas/ APO-1 ab-mediated killing in the presence of ActD or CHX does probably not result from impaired transcription or translation of the bcl-2 transgene. These results are consistent with the reported long half-life of the BCL-2 protein of 10-12 h (35) .
Glioma cells expressing murine bcl-2 were also more resistant to the cytotoxicity of TNFa in the presence of ActD and CHX (Fig. 5) . However, protection from TNF toxicity was moderate compared with protection from Fas/APO-I ab-induced killing. Previous reports on the role of bcl-2 in attenuating TNF toxicity are controversial (36) (37) (38) Figure 7 . Bcl-2 inhibits Fas/APO-l ab-mediated DNA fragmentation in human malignant glioma cells. Neo control glioma cells (left) or murine bcl-2-transfected clones (bcl-2) (right) were untreated, exposed to Fas/APO-l ab (1 HIgr/ml) for 24 h, to TNFa (10 ng/ml) for 24 h, or consecutively to TNFa and Fas/APO-l ab. Fragmented and intact DNA from 106 glioma cells were measured fluorometrically (6, 27) . Data are expressed as mean and SEM of percent DNA fragmentation (n = 3, *jP < 0.03 by t test for bcl-2 cells compared with neo cells).
augmentation of Fas/APO-1 ab-mediated apoptosis (6) . Quantitative DNA fluorometry showed that the bcl-2-mediated inhibition of Fas/APO-1 ab-induced cytotoxicity was associated with a significant reduction in DNA fragmentation (Fig. 7) . In line with the cytotoxicity data shown in Fig. 5 , the inhibition of DNA fragmentation was most prominent in bcl-2-transfected LN-18 cells and exceeded 50%. We observed that DNA fragmentation induced by Fas/APO-1 ab was only partially inhibited by the bc1-2 gene transfer even in experiments which showed complete abrogation of Fas/APO-1 ab-induced cell kill- 2638 Weller et al. (20) . Fas/APO-1 ab-induced DNA fragmentation was examined by DNA agarose gel electrophoresis in parallel with the experiments conducted to quantify bcl-2-mediated prevention of DNA fragmentation by DNA fluorometry (Fig. 7) . These experiments showed that neither LN-18 nor T98G neo control cells contained significant amounts of fragmented low-molecular weight DNA when DNA was extracted from 107 glioma cells exposed sequentially to TNFa and Fas/APO-l ab (data not shown). However, as previously described (6), DNA laddering became apparent in LN-229 exposed to TNFa and Fas/APO-1 ab, consistent with the quantitative DNA fragmentation data (Fig. 7) which yielded the highest percentage of DNA fragmentation under these conditions (17%). The cytotoxicity data presented in Fig. 5 (Fig. 8) . Further, the survival of neo control cells of the three glioma cell lines correlated with their previously reported endogenous BCL-2 protein levels which are highest in LN-229, moderately high in T98G, and low in LN-18, as assessed by Western blot (6) . No colony formation was observed when supernatants containing detached glioma cells were replated without prior centrifugation to remove residual Fas/APO-l ab (data not shown).
Bcl-2 enhances glioma cell survival after irradiation or exposure to chemotherapy drugs. Bcl-2 has received major attention as a mediator of resistance to irradiation and cancer chemotherapy drugs (9) . Since the latter are the two main adjuncts to the neurosurgical treatment of malignant glioma, we compared the survival of bcl-2 transfectants and neo control cells of the LN-18 and T98G glioma cell lines after irradiation or exposure to BCNU or cisplatin, two drugs used in the treatment of malignant glioma. Radioresistance was determined as the surviving fraction of glioma cells at 2 Gy (SF2) defined by the extent of proliferation relative to nonirradiated glioma cells 2 wk after irradiation (39) . Parent (Fig. 9 B) .
Bcl-2 clones of both cell lines exhibited enhanced survival after exposure to high concentrations of BCNU (Fig. 9 C) . Taken together, these data show that bcl-2 can protect glioma cells from irradiation and cytotoxic drugs. The extent of protection is determined by the cell line studied and the type of cytotoxic stimulus used.
Cooperative inhibition of Fas/APO-J ab-mediated apoptosis by bcl-2 and dexamethasone. Preexposure of human malignant glioma cells to dexamethasone attenuates Fas/APO-1 abmediated apoptosis (6) . Flow oma cell killing not only of neo control cells but also of the bcl-2 clones, suggesting that bcl-2 and dexamethasone target distinct steps in the killing cascade of Fas/APO-1-dependent apoptosis and might cooperate in vivo to inhibit immune-mediated glioma cell killing via Fas/APO-1.
Preexposure to cytokines overcomes bcl-2-mediated inhibition of Fas/APO-I -dependent glioma cell apoptosis. Preexposure to TNFa, IFNy, TGFf02, IL-1 and IL-8 enhances Fas/ APO-1 ab-mediated glioma cell killing of some glioma cell lines, including T98G and LN-229 (6) . In the present study, we have compared the effects of these cytokines on the expres-10 sion of Fas/APO-1 and bcl-2 with their effects on Fas/APO-1 ab-mediated apoptosis. TNFa, IFNy and IL-1 increased cell surface Fas/APO-1 expression whereas IL-8 and TGF/3 had no such effect (Table H ). In our previous study (6) , endogenous bc1-2 expression of the three glioma cell lines, LN-18, T98G, and LN-229, correlated with a requirement for cytokine-mediated presensitization to achieve maximal Fas/APO-1 ab-mediated apoptosis. Here we show that there are no significant differences in endogenous BCL-2 protein levels between untreated glioma cell cultures and cultures exposed to the cytokines (Table H), suggesting that cytokines induce sensitivity of glioma cells to Fas/APO-1 ab without directly modulating bcl-2 expression. Cytokines might therefore also counteract the protection of glioma cells from Fas/APO-1 ab-mediated apoptosis 10 mediated by murine bcl-2 gene transfer (Fig. 5) . Table III shows that bcl-2 clones of the T98G and LN-229 were no longer susceptible to presensitization with IL-1, IL-8 or TGF/3. However, they had not become refractory to IFNy-and TNFamediated sensitization to Fas/APO-1 ab-mediated killing. Even the T98G and LN-229 bcl-2 clones with the highest levels of bcl-2 expression were not completely protected from Fas/APO-1 ab-mediated apoptosis when presensitized with IFNy or TNFa. The bcl-2-mediated attenuation of Fas/APO-1 ab-mediated apoptosis after IFNy or TNFa preexposure (Table III) was moderate compared with the good protection from killing induced by Fas/APO-1 ab alone or in the presence of ActD or CHX (Fig. 5) (6) . Expression of the protooncogene bcl-2 has emerged as a major mechanism which allows tumor cells to resist physiological apoptosis and apoptosis induced by irradiation and chemotherapy drugs (9) .
This study illustrates that malignant gliomas express bcl-2 in vivo ( Fig. 1) and that forced expression of murine bcl-2 in glioma cell lines confers resistance to Fas/APO-l ab-mediated apoptosis (Fig. 5) . Prevention of Fas/APO-l ab-mediated glioma cell apoptosis by bcl-2 operated at a distal step of the apoptotic cascade triggered by Fas/APO-l ab, since forced bcl-2 expression did not reduce cell surface Fas/APO-l expression. Further, bcl-2 rescued a significant proportion of glioma cells from apoptosis which had suffered Fas/APO-l ab-induced DNA breaks, including those cells which had detached from on the basis of correlations between bcl-2 and Fas/APO-1 expression, for human peripheral blood cells (47) and lymphoid neoplasms (48, 49) . Further, coordinate expression of bcl-2 and Fas/APO-1 may limit the cycling of primed T cells which upon progressive differentiation lose bcl-2 and gain Fas/APO-1 expression (50) . Although the antiapoptotic actions of bcl-2 have been linked to antioxidant properties (51) , this action of bcl-2 is unlikely to be responsible for the prevention of Fas/ APO-1-dependent apoptosis since reactive oxygen intermediates have been excluded as mediators of Fas/APO-1 ab-induced cell death (52, 53) . Recent evidence implicates an acid sphingomyelinase in the TNF receptor-and Fas/APO-1 ab-triggered apoptotic pathway (54) . Our study then suggests that the broad spectrum of antiapoptotic actions of bcl-2 also encompasses apoptosis mediated through the sphingomyelinase pathway. BCL-2 protein expression was not restricted to human malignant glioma cell lines but was also detected in human malignant gliomas in vivo. BCL-2 immunoreactivity may correlate with malignant progression since BCL-2-positive tumor cells were more abundant in WHO grade III and IV astrocytomas than in grade I and H astrocytomas (Table I, Fig. 1 ). The expression of bcl-2 in gliomas indicates malignant transformation since untransformed astrocytes do not express BCL-2 protein in vivo (25, 33) . As previously reported for normal endothelial cells of brain and extracerebral tissues (24, 25) , endothelial cells in the glial tumors were BCL-2-negative. Cultured endothelial cells express Fas/APO-1 but are resistant to Fas/ APO-1 ab-mediated apoptosis (55) . Only endothelial cells of the central nervous system and of the fetal part of the placenta express Fas/APO-1 in vivo (44) . The expression of BCL-2 by tumor-infiltrating lymphocytes (Fig. 1) suggests that such immune effector cells could be harvested from gliomas and be expanded in vitro for cellular immunotherapy. However, glioma-derived tumor-infiltrating lymphocytes are rather refractory to activation and expansion in vitro (56) . In this regard, it is noteworthy that T cell apoptosis induced by TGF162, which may be responsible for glioma-induced T cell inactivation (57) (58) (59) , proceeds independently of bcl-2 expression in vitro (27) .
The present study suggests that the antiapoptotic properties of bcl-2 may interfere not only with Fas/APO-1-targeting immunotherapy of human malignant glioma but may also be involved in the resistance of these tumors to cancer chemotherapy and irradiation. The prevention of Fas/APO-1-dependent apoptosis of gliomas cells by dexamethasone was independent of bcl-2 expression and of cell surface Fas/APO-1 expression. Since most glioma patients receive steroids for the control of peritumoral edema, these effects of dexamethasone need to be considered in immunotherapy trials targeting Fas/APO-1. The cytoprotective effects of bcl-2 may be overcome by immunostimulatory cytokines like IFNy and TNFa. Although the application of IFNy and TNFa alone fails to induce regression of human malignant gliomas (60, 61) , these cytokines are tolerated by malignant glioma patients at concentrations likely to sensitize human malignant glioma cells to Fas/APO-1 ab-mediated apoptosis in vivo.
